ICON expects market conditions to remain similar through year-end, assuming persistent cancellation rates and mixed timing on biotech conversions. The company raised its full year revenue guidance to ...
Hosted on MSN
Icon signals $8B full-year revenue midpoint as metabolic and obesity trial momentum builds
Earnings Call Insights: ICON Public Limited Company (ICLR) Q2 2025 Full-year revenue guidance was updated to a new range of $7.85 billion at the low end and $8.15 billion at the high end, "increasing ...
SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Investors in ICON plc (NASDAQ: ICLR) saw the price of their shares drop about 49% during trading on February 12, 2026, after the company disclosed its ...
NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating ICON plc (NASDAQ: ICLR) following the company's disclosure on February 12, 2026, that an internal accounting ...
Full-year revenue guidance was updated to a new range of $7.85 billion at the low end and $8.15 billion at the high end, "increasing the midpoint to $8 billion." The full-year adjusted earnings per ...
Hosted on MSN
Icon outlines $8.05B-$8.1B 2025 revenue target as margin pressure persists, supported by strong RFP flow
Earnings Call Insights: ICON Public Limited Company (ICLR) Q3 2025 Steven Cutler reflected on his tenure, noting ICON's growth from 8,500 to 40,000 employees and its rise in industry ranking. He ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results